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Neutropenia secondary to chemotherapy in breast cancer patients can be life-
threatening and there are no biomarkers available to predict the risk of drug-induced
neutropenia in those patients. We previously performed a genome-wide association
study (GWAS) for neutropenia events in women with breast cancer who were treated
with 5-fluorouracil, epirubicin and cyclophosphamide and recruited to the SUCCESS-
A trial. A genome-wide significant single-nucleotide polymorphism (SNP) signal in
the tumor necrosis factor superfamily member 13B (TNFSF13B) gene, encoding the
cytokine B-cell activating factor (BAFF), was identified in that GWAS. Taking advantage
of these existing GWAS data, in the present study we utilized a pathway-based analysis
approach by leveraging knowledge of the pharmacokinetics and pharmacodynamics of
drugs and breast cancer pathophysiology to identify additional SNPs/genes associated
with the underlying etiology of chemotherapy-induced neutropenia. We identified
three SNPs in the hyaluronan mediated motility receptor (HMMR) gene that were
significantly associated with neutropenia (p < 1.0E-04). Those three SNPs were trans-
expression quantitative trait loci for the expression of TNFSF13B (p < 1.0E-04). The
minor allele of these HMMR SNPs was associated with a decreased TNFSF13B
mRNA level. Additional functional studies performed with lymphoblastoid cell lines
(LCLs) demonstrated that LCLs possessing the minor allele for the HMMR SNPs
were more sensitive to drug treatment. Knock-down of TNFSF13B in LCLs and
HL-60 promyelocytic cells and treatment of those cells with BAFF modulated the
cell sensitivity to chemotherapy treatment. These results demonstrate that HMMR
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SNP-dependent cytotoxicity of these chemotherapeutic agents might be related to
TNFSF13B expression level. In summary, utilizing a pathway-based approach for the
analysis of GWAS data, we identified additional SNPs in the HMMR gene that were
associated with neutropenia and also were correlated with TNFSF13B expression.
Keywords: breast cancer, neutropenia, HMMR, TNFSF13B, GWAS
INTRODUCTION
Breast cancer is the most common invasive cancer in women
worldwide and approximately 1.3 million cases are diagnosed
worldwide annually (Ferlay et al., 2015). Those patients
with high-risk features require chemotherapy following
surgical resection of the tumor. However, administration of
chemotherapy regimens such as cytotoxic agents potentially
leads to life-threatening adverse drug effects, of which the most
common adverse event is chemotherapy-induced neutropenia
(CIN) (Fontanella et al., 2014). This adverse event is common
in breast cancer patients receiving adjuvant chemotherapy and
affects more than 50% of patients (Holmes et al., 2002; Therasse
et al., 2003). More than 20% of patients with breast cancer
receiving adjuvant chemotherapy developed febrile neutropenia,
which is a more severe, life-threatening adverse event (Do et al.,
2015). CIN may lead to infection and hospitalization, which
potentially results in compromised treatment because of the
requirement for reduction in dose intensity of the chemotherapy
regimen (Link et al., 2001; Fontanella et al., 2014; Agiro et al.,
2016). To prevent CIN, co-administration of white blood cell
growth factor such as the granulocyte colony-stimulating growth
factor (G-CSF) is recommend with chemotherapy (Smith et al.,
2015), and has shown benefit in patients with breast cancer
who received chemotherapy (Holmes et al., 2002; Vogel et al.,
2005; Agiro et al., 2016). However, considerable inter-individual
variabilities in both risk and severity of CIN, and in the beneficial
effect of G-CSF prophylaxis were found among breast cancer
patients (Agiro et al., 2016). Sub-classification of patients
at increased risk of CIN may allow for improved treatment
modifications, such as G-CSF support, dose reduction, or use of
chemotherapy regimens with a lower risk of myelosuppression.
Clinical risk factors such as older age, poor nutrition and prior
chemotherapy have been associated with increased risk of febrile
neutropenia (Aapro et al., 2006). However, predictive models
using these factors for risk of CIN have shown limited utility
(Lyman et al., 2015). Other predictors for CIN risk are urgently
needed which may help to improve the individualized care of
breast cancer patients during adjuvant chemotherapy.
Germline genetic polymorphisms in patients with cancer
have been associated with risk for chemotherapy-related toxicity,
including CIN (Ulrich et al., 2003; Pinto et al., 2012). Using a
candidate gene approach, previous studies have demonstrated
that single-nucleotide polymorphisms (SNPs) in genes encoding
drug-metabolizing enzymes and transporters were associated
with the risk for CIN in breast cancer patients (Low et al.,
2009; Yao et al., 2010; Okishiro et al., 2012; Tang et al., 2013).
However, those studies included a limited number of SNPs/genes
and relatively small sample sizes, which might explain the
contradictory results among these studies — e.g., no SNPs/genes
were replicated from one study to another even though the
same chemotherapy regimens were administrated to those breast
cancer patients. To our knowledge, no genome-wide association
study (GWAS) for CIN has been reported. Compared to the
candidate gene approach, GWAS is an “unbiased” approach that
has the capability of revealing novel genetic variants associated
with drug response (Weinshilboum and Wang, 2004; Wang et al.,
2011; Motsinger-Reif et al., 2013). We have previously performed
GWASs for adverse events in breast cancer patients treated
with aromatase inhibitors and identified novel genetic variants
associated with musculoskeletal pain (Ingle et al., 2010) and bone
fractures (Liu et al., 2014). Recently, we performed a GWAS for
CIN in 3,252 women with early stage breast cancer who received
adjuvant chemotherapy. Novel SNP signals that were genome-
wide significantly associated with CIN were identified in that
GWAS. That GWAS will be reported in detail elsewhere.
Although GWAS has been very successful for identifying
novel and statistically significant SNPs that were associated with
phenotypes, many SNPs/genes that have biological significance
could be overlooked in GWAS since those SNPs do not
meet the threshold to reach genome-wide significance (Wang
et al., 2007, 2010). To overcome this problem, pathway-based
approaches, which consider prior knowledge of genes and
pathways contributing to the phenotype of interest has been
developed to provide additional insight into the interpretation
of GWAS data on complex phenotypes (Wang et al., 2007;
Ramanan et al., 2012). This approach has been successfully used
to analyze and interpret GWAS data for many clinical phenotypes
(Torkamani et al., 2008; Baranzini et al., 2009; Holmans et al.,
2009; Ballard et al., 2010; Jia et al., 2010)
In the present study, we took advantage of the GWAS data
we generated for CIN in breast cancer patients, and performed
pathway-based analysis to identify SNPs/genes that might be
associated with CIN. The SNPs identified by this pathway-based
analysis were pursued by functional characterization to help us
understand underlying mechanisms.
MATERIALS AND METHODS
Patients and the Clinic Trial
Patients in this study were recruited to the SUCCESS-A
trial (ClinicalTrials.gov Identifier: NCT02181101), a randomized
Phase III study of response to the treatment of early primary
breast cancer with adjuvant therapy after surgical resection
(Rack et al., 2014; Widschwendter et al., 2015). All patients
initially received three cycles of epirubicin, 5-fluorouracil (5-FU),
and cyclophosphamide. Patients were then randomized to
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either receive three cycles of either gemcitabine in addition to
docetaxel or docetaxel alone. A second randomization consisted
of zoledronate at the conclusion of treatment for either 2 or
5 years. This trial recruited 3754 patients over 18 months in
251 medical centers in Germany, and accrual ended in March
2007. The main study and all pre-specified translational research
projects, including the one reported here, were approved by
all of the responsible ethics committees and were conducted in
accordance with the Declaration of Helsinki. This study was also
reviewed and approved by the Mayo Clinic Institutional Review
Board. All patients gave written informed consent.
Case Definition for Neutropenia and
GWAS
Cases were defined as patients who had at least one of the
following events: leukopenia, neutropenia or febrile neutropenia,
during cycles one to three of chemotherapy with epirubicin,
5-fluorouracil (5-FU), and cyclophosphamide. Cases were
required to meet the toxicity level of Grade 3 or 4 based on
the National Cancer Institute (NCI)’s Common Terminology
Criteria for Adverse Events v3.0. A total of 1648 patients fulfilled
the criteria for cases. Other patients served as controls for the
GWAS analysis. Patient DNA samples were genotyped on the
Illumina HumanOmniExpress-12v1 G FFPE array (Illumina,
San Diego, CA, United States). After remove of 5 related
patients and 9 patients who were non-Caucasian (Asian), a
total of 3,252 patients (1,635 controls vs. 1,617 cases) who
passed QC for genotyping and whose covariate information
(Supplementary Table S1) was available were included in the
GWAS analysis. Imputation was performed based on 1000
Genomes Project data (Howie et al., 2012). Genotyped SNPs
which had a p-value < 1.0E-05 in the initial GWAS were used as
input SNPs to perform imputation. Genotyping and imputation
are described in detail in the Supplementary Methods. Data
that were generated in the SUCCESS-A trial, including genotype
and clinical phenotype data, as well as a further descriptions of
materials can be found in the NCBI database of Genotypes and
Phenotypes (dbGaP Study Accession: phs000547.v1.p).
Selection of Pathways, Genes and SNPs
Genes involved in pathways of (1) the pharmacokinetics (PK)
and pharmacodynamics (PD) for the chemotherapeutic drugs
used in the SUCCESS-A trial, cyclophosphamide, epirubicin
and 5-FU were included in this analysis. These candidate genes
were identified using the PharmGKB database1. Genes involved
in the PK/PD of doxorubicin, an analog of epirubicin, were
selected because epirubicin is not included in the PharmGKB.
(2) Pathways that were shown to be aberrant in breast cancer
according to The Cancer Genome Atlas (TCGA) data were
included in the analysis (The Cancer Genome Atlas Network,
2012). Those pathways were the PI3K, mTOR, p53, apoptosis, and
checkpoint signaling pathways. Genes in these pathways were
identified using the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database (Kanehisa and Goto, 2000). (3) The PAM50
genes which have been shown to be effective in predicting disease
1www.pharmgkb.org
prognosis (Nielsen et al., 2010) were also included. (4) Finally,
genes studied in our laboratory shown to be functionally relevant
in the AKT/mTOR signaling pathways in chemotherapy response
(Pei et al., 2009; Hou et al., 2014; Yu et al., 2017) and toxicity
(Ingle et al., 2010) were also added to the analysis.
SNPs within 50 kb up- and down-stream, and across the
selected genes as described above were included in this analysis.
SNPs that were located > 50 kb away from a gene might
also affect gene transcription and function. Those SNPs will be
overlooked in this study. Genotyping information for SNPs in
those pathway genes in the SUCCESS-A patients was obtained
from our GWAS genotyping data. Imputation was performed
based on 1000 Genomes Project data (Howie et al., 2012). See
Supplementary Methods for details.
Association of SNPs With Neutropenia
The analysis for association of SNPs with neutropenia was based
on conditional logistic regression to account for the matched
design. SNP genotypes were coded as additive effects on the
log OR by coding 0, 1, or 2 for the minor allele count.
A likelihood ratio test with one degree of freedom for each SNP
was then determined. The primary covariates (Supplementary
Table S1) used to match cases and controls were controlled
in the conditional logistic regression. Association analyses were
performed in R2, SAS (SAS Institute Inc.) and PLINK. Logistic
regression models were used to calculate Odds ratios (ORs), 95%
confidence intervals (CIs), and p-values, following corrections for
multiple testing.
eQTL Analysis
Single-nucleotide polymorphisms of interest that were associated
with neutropenia were further subjected to expression
quantitative trait loci (eQTL) analysis using our lymphoblastoid
cell line (LCL) data sets, which have been described in detail
in our previous studies (Li et al., 2008, 2014; Niu et al., 2010;
Matimba et al., 2014; Liu et al., 2017). The Human Variation
Panel of LCLs from 96 European-American (EA), 95 African-
American (AA), and 96 Han Chinese-American (HCA) healthy
subjects were obtained from the Coriell Institute. Those LCLs
are B-lymphocytes that were immortalized by Epstein Barr
Virus (EBV) infection. Genome-wide genotype data and mRNA
expression data for these LCLs have been generated in our
laboratory by using the Illumina 550K and 510S SNP BeadChips
(Illumina, San Diego, CA, United States), and the Affymetrix
Human Genome U133 Plus 2.0 GeneChip arrays (Affymetrix,
Santa Clara, CA, United States), respectively. Genotype and
gene expression data were deposited in the National Center for
Biotechnology Information Gene Expression Omnibus (GEO
accession: GSE23120). Expression array data were normalized
on a log2 scale using GCRMA (Wu et al., 2004). The normalized
expression data were then regressed on gender. Partial Pearson
correlations were used to quantify the association between SNPs
and mRNA expression. Since the LCLs were from multiple
races/ethnic groups, before completing the genetic association
analysis, population stratification was assessed using the method
2http://www.r-project.org
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developed by Price et al. (2006) as described in detail previously
(Niu et al., 2010). These partial correlations were tested using a
Wald test. False discovery q-values (Storey and Tibshirani, 2003)
were also computed for each test.
Cell Culture and Cytotoxicity Assays
Lymphoblastoid cell lines were cultured in RPMI 1640
media containing 15% fetal bovine serum (FBS). The human
promyelocytic leukemia cell line, HL-60, was obtained from
the American Type Culture Collection (ATCC, Manassas,
VA, United States), and was cultured in RPMI 1640 media
containing 10% FBS. Epirubicin (EPI) was purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, United States).
Mafosfamide (MFF) was purchased from Toronto Research
Chemicals Inc. (Toronto, Canada). MFF can spontaneously
decompose to 4-hydroxy-cyclophosphamide, the active
metabolite of cyclophosphamide, when added in culture
media (Mazur et al., 2012). Fluorouracil (5-FU) was purchased
from Sigma-Aldrich (St. Louis, MO, United States). Cytotoxicity
assays with LCLs and HL-60 cells were performed with the
CellTiter 96 R© Aqueous Non-Radioactive Cell Proliferation
Assay (Promega Corporation, Madison, WI, United States)
in 96 well plates (Corning, Corning, NY, United States)
at a density of 5 × 105 cells/mL (100 µL/well). 10 µL
of 5-FU (500–0.01 µM), epirubicin (10–0.0005 µM), or
mafosfamide (100–0.005 µM) were added into the wells
and incubated at 37◦C for 72 h. Plates were then added
with 20 µL of MTS buffer and read in an Infinite M1000
PRO plate reader (Tecan AG, Switzerland) after incubation
for 3 h. Relative cell viability was then plotted against drug
concentration to derive a cytotoxicity curve. Experiments were
independently repeated at least twice with triplicate wells for each
treatment. Independent t-test was used to determine statistical
significance.
mRNA Quantification
Messenger RNA levels were quantified by quantitative reverse
transcription PCR (qRT-PCR) using Power SYBRTM Green RNA-
to-CTTM 1-Step Kit (Applied Biosystems Inc., Foster City, CA,
United States). Total RNA was extracted from cells by the RNeasy
Plus Mini Kit (QIAGEN, Germany). A total of 100 ng of total
RNA was used for each reaction. Specific primers for TNFSF13B
mRNA were purchased from Integrated DNA Technologies
(Coralville, IA, United States). The qRT-PCR reaction was
performed using the Stratagene Mx3005P Quantitative Real-
Time PCR detection system (Agilent Technologies, Santa Clara,
CA, United States). Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was used as an internal control.
TNFSF13B KD and Ligand Treatment for
Cytotoxicity Assays
LCLs and HL-60 cells were incubated at a density of 1 × 106
cells/mL in RPMI 1640 with 5% charcoal-stripped FBS for 24 h
followed by serum free medium for an additional 24 h. For
TNFSF13B KD, cells were transfected with negative control and
TNFSF13B siRNAs (Dharmacon, Lafayette, CO, United States)
separately, and incubated in RPMI 1640 with 5% charcoal-
stripped FBS overnight before cytotoxicity assay. For TNFSF13B
ligand (BAFF) treatment, recombinant human BAFF (Cell
Signaling Technology, Danvers, MA, United States) reconstituted
in PBS containing 200 µM dithiothreitol (DTT) and 0.02%
bovine serum albumin was added to the cell culture media
at a final concentration of 1 µg/mL and were incubated for
24 h. Vehicle treatment that included DTT and BSA but
without BAFF was performed as control. After KD and BAFF
treatment, cytotoxicity assays were performed as describe above.
Experiments were repeated independently three times.
RESULTS
A summary of the patients’ characteristics is listed in the
Supplementary Table S1. A GWAS for CIN in women with early
stage breast cancer who were enrolled in the SUCCESS-A trial
has been completed. The Manhattan plot of the GWAS for CIN in
women with breast cancer during three cycles of epirubicin, 5-FU,
and cyclophosphamide treatment, is shown in Supplementary
Figure S1. Two genome-wide significant (p < 5.0E-08) SNP
signals were identified, including one that mapped to the
TNFSF13B gene on chromosome 13, with lowest p-value of 2.4E-
08. TNFSF13B encodes a cytokine known as B-cell activating
factor (BAFF) which plays an important role in the proliferation
and differentiation of B-cells (Mackay and Browning, 2002).
Taking advantages of the existing GWAS data, we utilized
a pathway-based approach by considering prior knowledge of
these drugs and the disease, to identify additional SNPs/genes that
might be associated with neutropenia.
Pathway-Based Genes and SNPs
Ninety-five candidate genes involved in the PK and PD pathways
of the chemotherapeutic drugs used in the SUCCESS-A trial were
identified (Supplementary Table S2). In addition, 311 genes were
identified in pathways that were shown to be aberrant in breast
cancer according to TCGA data (The Cancer Genome Atlas
Network, 2012) were included (Supplementary Table S3). The 50
genes in the PAM50 gene list (Supplementary Table S4) which
have been shown to be effective in predicting disease prognosis
(Nielsen et al., 2010), and 12 genes that had been identified
in previous cancer studies in our laboratory (Supplementary
Table S5) were also added to the analysis. A summary of the
pathways, number of genes and SNPs is listed in Table 1. Several
genes were included in multiple pathways and overlapping SNPs
were removed during the follow up analysis. Finally, a total of
325, 934 SNPs were included in the analysis for association with
CIN in breast cancer patients.
SNP Associations With Neutropenia and
eQTL Analysis
Genotypes of selected SNPs in the pathway genes were associated
with the CIN phenotype in patients recruited in the SUCCESS-
A trial. A total of 35 SNPs were identified that were associated
with CIN with a p-value < 1.0E-04 (Table 2). The associations
listed in Table 2 are “nominal” and have not been corrected
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TABLE 1 | Pathways and numbers of genes and single-nucleotide polymorphisms (SNPs) involved in pathways included in the analysis and the number of SNPs that
were associated with neutropenia.
Pathway Pathway gene source Number of pathway
genes
Number of SNPs in
pathway genes
Number of SNPs associated with
neutropenia (p < 1.0E-04)
Cyclophosphamide PK/PD PharmGKB 40 17,548 1
Doxorubicin PK/PD PharmGKB 30 18,879 5
5-Fluorouracil PK/PD PharmGKB 28 21,063 1
Apoptosis TCGA/KEGG 72 47,321 1
Checkpoint TCGA/KEGG 46 27,072 4
P53 signaling TCGA/KEGG 88 53,318 24
mTOR signaling TCGA/KEGG 98 69,486 17
PI3K signaling TCGA/KEGG 100 63,853 15
PAM50 PAM50 50 31,550 0
AKT/mTOR signaling “In house” 12 7,394 0
PK, pharmacokinetics; PD, pharmacodynamics; PAM50, prediction analysis of microarray 50; PharmGKB, www.pharmgkb.org; TCGA, The Cancer Genome Atlas; KEGG,
Kyoto encyclopedia of genes and genomes; “In house” means the pathway and gene were previously characterized in this laboratory.
for multiple comparisons because the purpose was to identify
SNPs/genes for functional validation. None of those SNPs was
located in an exon or was a splicing variant. We then set out to
determine whether those SNPs were either cis- or trans-eQTLs.
To do that, we performed eQTL analysis using the 300 LCLs for
which genome-wide SNP genotype and mRNA expression data
had been generated in our lab (Niu et al., 2010). Six SNPs with
very low MAFs (<0.010) were not applicable for eQTL analysis in
those 300 LCLs because the number of LCLs with the variant SNP
allele was too small to compare with LCLs with WT genotypes
(Table 2). For other SNPs that underwent eQTL analysis, none
SNPs were cis-eQTLs. However, we identified nine SNPs that
were trans-eQTLs (Table 2). Interestingly, three SNPs, rs299293,
rs299313, and rs299314, which were located in the hyaluronan
mediated motility receptor (HMMR) gene, were trans-eQTLs for
TNFSF13B (Figure 1A and Supplementary Table S6), one of
the “top” hits identified in the original GWAS for neutropenia
(Supplementary Figure S1). These 3 HMMR SNPs were in tight
linkage disequilibrium (LD) (r2 > 0.87) and belonged to the
same haplotype. The genotypes for those 3 SNPs in an LCL were
matched – e.g., an LCL with homozygous variant genotype for
one of those 3 SNPs was also homozygous variant genotype for
the other two SNPs. These 3 HMMR SNPs were imputed SNPs
in the pathway-based analysis, and they were excluded from the
GWAS because none of the genotyped SNPs in LD with these
three SNPs had a p-value < 1.0E-05, the cut-off value for input
SNPs to perform imputation for GWAS analysis. The rs299293
SNP was located in intron 12, and the rs299313 and rs299314
SNPs were in intron 16 of HMMR. Those 3 SNPs mapped to the 3′
end of the cyclin G1 (CCNG1) gene which is involved in the p53
signaling pathway. However, those three SNPs were not eQTLs
for either HMMR (Figure 1B) or CCNG1 (Figure 1C) mRNA
expression in LCLs.
HMMR SNP-Dependent Cytotoxicity
To confirm that the SNPs in the HMMR gene were associated
with neutropenia, we performed cytotoxicity assays for drugs
used in the SUCCESS-A trial using the LCLs with WT and variant
genotypes for the HMMR SNPs. Six LCLs with variant SNP
genotypes and six with WT genotype were chosen randomly for
cytotoxicity assay. Since only two LCLs with homozygous variant
genotypes for those SNPs were available, four LCLs heterozygous
variant for those SNPs were included in the variant group. To
confirm genotypes for those three SNPs in HMMR which were
imputed based on the 1K Genome data, DNA sequencing was
performed for those SNPs in these 12 LCLs that were later
used in cytotoxicity assays. We found that LCLs possessing
the variant HMMR SNP genotypes were more sensitive to all
three agents, 5-FU, MFF, and EPI (Figures 2A–C). This result
was consistent with our clinical observations in patients treated
with these drugs. Patients with the variant SNP genotype had
a higher risk of neutropenia compared to patients with the
WT SNP genotype (OR = 1.36) (Table 2). The eQTL analysis
for those HMMR SNPs indicated that the SNPs were trans-
eQTLs for TNFSF13B and variant SNP genotypes were associated
with decreased TNFSF13B mRNA level (Figure 1A). To further
determine TNFSF13B mRNA levels in those 12 LCLs that were
used for cytotoxicity assays, qRT-PCR for TNFSF13B mRNA
were performed with total RNA extracted from those LCLs. The
average mRNA level of TNFSF13B in six LCLs with variant SNP
alleles was significantly decreased compared with six LCLs with
WT genotype (p = 0.006) (Figure 2D), a result consistent with
the eQTL analysis (Figure 1A). The mRNA levels of TNFSF13B,
HMMR, and CCNG1 in 12 LCLs that were determined by
mRNA microarray again indicated a decrease in the TNFSF13B
mRNA in LCLs with variant SNP genotypes but no significant
changes in the HMMR and CCNG1 mRNA levels (Supplementary
Figure S2).
TNFSF13B and Chemo-Drug Sensitivity
To further demonstrate that TNFSF13B expression was
important for the sensitivity to these chemotherapeutic agents,
we performed a cytotoxicity assay in an LCL with relatively high
TNFSF13B expression after knock-down (KD) of TNFSF13B.
The same cytotoxicity assay was also performed with a human
promyelocytic leukemia cell line, HL-60, a cell representative
of promyelocytes which can differentiate to myelocytes, the
major components of white blood cells. These cells were
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TABLE 2 | Single-nucleotide polymorphisms (SNPs) associated with risk for chemotherapy-induced neutropenia (p < 1.0E-04) in women with breast cancer recruited to
the SUCCESS-A trail (n = 3252) and expression quantitative trait loci (eQTL) analysis in lymphoblastoid cell lines (LCLs).
SNP rs ID Chr. Common allele Minor allele OR MAF p-value Gene Pathway eQTL in LCLs
rs144991623 13 C T 69.8 0.002 5.98E-06 FOXO1 Checkpoint, PI3K NA
rs9389568 6 T C 0.59 0.049 7.10E-06 PERP P53 Yes
rs8110364 19 G A 3.09 0.011 2.23E-05 PIK3R2 mTOR, PI3K, P53 Yes
rs56022120 19 C T 3.12 0.011 2.29E-05 PIK3R2 mTOR, PI3K, P53 No
rs150688309 19 C G 2.87 0.013 2.67E-05 PIK3R2 mTOR, PI3K, P53 No
rs58695150 19 C T 3.07 0.011 3.15E-05 PIK3R2 mTOR, PI3K, P53 Yes
rs299293 5 C T 1.36 0.133 3.19E-05 HMMR/CCNG1 P53 Yes
rs138602176 19 G A 2.97 0.011 3.24E-05 PIK3R2 mTOR, PI3K, P53 No
rs148235907 19 G A 3.06 0.011 3.35E-05 PIK3R2 mTOR, PI3K, P53 No
rs117951771 19 C T 3.06 0.011 3.37E-05 PIK3R2 mTOR, PI3K, P53 No
rs299314 5 T C 1.35 0.138 3.60E-05 HMMR/CCNG1 P53 Yes
rs299313 5 G A 1.35 0.139 3.72E-05 HMMR/CCNG1 P53 Yes
rs115457081 2 G A 5.04 0.012 3.89E-05 IRS1 mTOR No
rs117341846 19 C T 3.03 0.011 3.93E-05 PIK3R2 mTOR, PI3K, P53 No
rs4968187 17 C T 0.10 0.004 4.09E-05 TP53 5FU, Apoptosis,
Checkpoint,
Doxorubicin, PI3K, P53
NA
rs142244113 19 C T 1.72 0.039 4.59E-05 INSR mTOR No
rs79430272 19 C T 2.94 0.011 4.80E-05 PIK3R2 mTOR, PI3K, P53 No
rs118129530 19 G A 3.00 0.011 4.82E-05 PIK3R2 mTOR, PI3K, P53 No
rs77769901 14 A G 0.31 0.012 4.99E-05 CCNK P53 No
rs145623321 19 C T 3.01 0.010 5.35E-05 PIK3R2 mTOR, PI3K, P53 No
rs148013902 19 C T 3.01 0.010 5.46E-05 PIK3R2 mTOR, PI3K, P53 No
rs55633228 19 C T 3.00 0.010 5.59E-05 PIK3R2 mTOR, PI3K, P53 No
rs141084494 22 G A 0.05 0.003 6.26E-05 RBX1 Checkpoint NA
rs41412545 19 C A 1.70 0.038 6.36E-05 INSR mTOR No
rs3805945 6 T C 1.68 0.040 6.81E-05 PPP2R5D mTOR No
rs117101815 6 G T 0.63 0.051 7.17E-05 PERP P53 Yes
rs9402944 6 G T 0.63 0.051 7.20E-05 PERP P53 Yes
rs181501757 17 G A 4.77 0.008 7.75E-05 TOP2A Doxorubicin NA
rs149212925 12 A G 0.00 0.001 8.33E-05 NOS1 Doxorubicin NA
rs112783657 21 C T 0.49 0.027 8.65E-05 CBR3 Doxorubicin No
rs74743371 21 G T 0.49 0.027 8.68E-05 CBR3 Doxorubicin No
rs117458836 10 G A 2.53 0.014 8.85E-05 CYP2C8 Cyclophosphamide No
rs118088833 11 C T 0.26 0.009 8.99E-05 TP53AIP1 P53 NA
rs112242273 3 C T 0.52 0.038 9.58E-05 GNL3 Checkpoint, P53 No
rs78428806 6 G A 0.63 0.048 9.79E-05 PERP P53 Yes
Chr., chromosome; OR, odds ratio; MAF, minor allele frequency; NA, not applicable, because SNP MAF is too low to find LCLs with variant SNP allele. The three SNPs in
HMMR gene were highlighted in bold.
more sensitive to 5-FU and MFF treatment, but not EPI
treatment, in both cell lines (Figures 3A,C) after TNFSF13B KD
(Figures 3B,D) when compared with the negative control KD.
Since TNFSF13B encodes a cytokine known as BAFF, we also
performed cytotoxicity assays in the LCL and HL-60 cells with
BAFF treatment. Both the LCL and HL-60 that were treated with
recombinant human BAFF showed dose-dependent resistance
to 5-FU and MFF treatment (Figures 4A,B, left and middle) but
were not significantly changed by EPI treatment (Figures 4A,B,
right).
We did not observe significant changes in EPI sensitivity
in both LCL and HL-60 cells after TNFSF13B KD or BAFF
treatment, while LCLs with variant SNP genotypes were more
sensitive to EPI (Figure 2C). This might indicate additional
mechanisms beyond TNFSF13B expression that are related to
those SNP genotypes could contribute to EPI cytotoxicity.
Although the HMMR SNPs were trans-eQTLs for TNFSF13B, we
did not observe any correlation between HMMR and TNFSF13B
mRNA expression based on the mRNA data from the 300
LCLs. We also measured TNFSF13B mRNA level after KD of
HMMR and CCNG1, but no change in TNFSF13B mRNA was
observed (data not shown). The HMMR mRNA level was also
quantified after LCLs were treated with 5-FU, EPI, and MFF
at the concentration of their IC50s, respectively. Compared to
vehicle treatment, HMMR mRNA level (relative to GAPDH)
was not significantly changed after LCLs were exposed to 5-FU
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FIGURE 1 | Expression quantitative trait loci (eQTL) analysis for hyaluronan mediated motility receptor (HMMR) single-nucleotide polymorphisms (SNPs) (rs299293,
rs299313, and rs299314) in lymphoblastoid cell lines (LCLs). These three HMMR SNPs belong to a same haplotype and their genotypes were same in each LCLs.
The mRNA level of (A) TNFSF13B, (B) HMMR, and (C) CCNG1 were grouped based on the genotype of HMMR SNPs, and compared by one-way ANOVA.
A p-value < 0.05 was considered statistically significant. The mRNA level was measured by the Affymetrix U133 Plus 2.0GeneChip expression array with specific
probes as specified. Values are mean ± SEM for mRNA level in LCLs with wild type (W/W, n = 247), heterozygous variant (W/V, n = 35) and homozygous variant
(V/V, n = 2) genotypes (showed in red line and error bars), respectively.
FIGURE 2 | Cytotoxicity for LCLs with different genotypes for HMMR SNPs. Average cytotoxicity for (A) fluorouracil (5-FU), (B) mafosfamide (MFF), and (C)
epirubicin (EPI) in LCLs with W/W genotypes (n = 6) vs. LCLs with V/V and W/V genotypes (n = 2+4). Cell viability was tested by MTS assay after 72 h of drug
exposure. Relative cell viability was plotted against drug concentration to derive a cytotoxicity curve. Cytotoxicity for each LCL was averaged from triplicate
determinations. Values represent mean ± SEM of LCLs in each genotype group. (D) TNFSF13B mRNA level in LCLs that are used for cytotoxicity assay were
determined by qRT-PCR and grouped based on the HMMR SNP genotype. Values are mean ± SEM and compared by unpaired t-test. A p-value < 0.05 was
considered statistically significant. ∗∗p < 0.01.
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FIGURE 3 | Cytotoxicity for LCLs and HL-60 after TNFSF13B Knockdown. (A) Cytotoxicity for one of the LCLs, CA11, treated with 5-FU (left), MFF (middle), and EPI
(right) after knockdown (KD) of TNFSF13B. (B) TNFSF13B mRNA level in LCL CA11 after 24 h of transfection of TNFSF13B siRNA vs. non-targeting scrambled
control (Neg.) siRNA. (C) Cytotoxicity for HL-60 cells treated with 5-FU (left), MFF (middle) and EPI (right) after knockdown (KD) of TNFSF13B. (D) TNFSF13B mRNA
level in HL-60 after 24 h of transfection of TNFSF13B siRNA vs. non-targeting scrambled control (Neg.) siRNA. Values represent mean ± SEM from triplicate
determinations.
(50 µM) and/or EPI (0.1 µM). Although HMMR mRNA levels
were slightly decreased (∼15%) in LCLs after exposure to MFF,
no significant differences were observed between WT and variant
LCLs (data not shown). The molecular mechanism for SNPs in
HMMR that was associated with TNFSF13B expression needs to
be further explored.
In summary, this series of functional genomic experiments
confirmed that three SNPs in the HMMR gene were associated
with the cytotoxicity of drugs used in the SUCCESS-A trial,
an effect which is probably mediated through the expression of
TNFSF13B.
DISCUSSION
In the present study, we took advantage of GWAS data that we
had generated in the SUCCESS-A trial, and utilized a pathway-
based approach to identify additional biomarkers and underlying
biology for CIN in breast cancer patients. Specifically, SNPs in
genes involved in PK and PD pathways for the chemotherapy
agents that were used to treat patients, and were involved
in disease risk were associated with neutropenia events. We
identified additional SNPs with low p-value that were associated
with CIN, including SNPs in HMMR that are trans-eQTLs for
TNFSF13B, one of the genome-wide significant signals identified
in the original GWAS (Supplementary Figure S1). The variant
HMMR SNP genotype was associated with decreased TNFSF13B
expression (Figure 1A) and higher risk of CIN (Table 2).
To further eliminate potential false positives results and to
understand the underlying biology of these SNPs, we performed
functional studies to further validate the association results.
We demonstrated that LCLs carrying variant genotypes for the
HMMR SNPs displayed decreased expression of TNFSF13B, and
were more sensitive to treatment with 5-FU, mafosfamide and
epirubicin (Figure 2). Further cytotoxicity assays conducted with
TNFSF13B KD and TNFSF13B cytokine (BAFF) treatment in
both LCL and HL-60 promyelocytic cells suggested that the
modulation of TNFSF13B expression altered sensitivity to those
chemotherapy agents (Figures 3, 4). This study not only enabled
us to discover additional SNPs associated with CIN, but also
indicated an association with TNFSF13B expression.
The three HMMR SNPs that were identified by our pathway-
based analysis were missed in the GWAS for CIN, probably
because those SNPs did not directly contribute to CIN in
breast cancer patients but rather through the expression of
TNFSF13B. The HMMR gene encodes HMMR which is involved
in cell motility. HMMR has been implicated in the pathogenesis
of tumors like breast cancer and inflammatory disorders like
osteoarthritis (Misra et al., 2015). We have demonstrated that
SNPs within HMMR are associated with risk for CIN and that
those SNPs are also trans-eQTLs for TNFSF13B expression.
However, KD of HMMR did not directly affect TNFSF13B
expression in the cell lines that we tested. HMMR has not
been shown to be involved in the mechanism of treatment
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FIGURE 4 | Cytotoxicity assays for (A) one of the LCLs, CA11, and for (B) HL-60 that were treated with 5-FU (left), MFF (middle) and EPI (right) with incubation of
human recombinant B-cell activating factor (BAFF) at different doses. Values represent mean ± SEM from triplicate determinations.
related neutropenia and the mechanism for how it might be
associated with TNFSF13B expression is unclear and should be
further explored. The association between HMMR SNPs and CIN
in breast cancer patients needs to be further validated in an
independent data set.
TNFSF13B encodes a cytokine known as BAFF, which is
synthesized primarily by myeloid cells and is required for survival
of B-cells. It is up-regulated in autoimmune diseases and various
B-cell malignancies (Shivakumar and Ansell, 2006). Although it
is involved primarily in B-cell survival, there has been increasing
evidence that it may also be involved in reverse signaling in
the activation of myeloid cells as well (Chang et al., 2006; Jeon
et al., 2010). The role of this growth factor in the activation
of myeloid cells is not fully understood and there is conflicting
evidence that it is not involved in myeloid cell activation (Nys
et al., 2013). Previous studies reported that serum BAFF levels
were increased in patients who developed late onset neutropenia
after therapy with rituximab (Terrier et al., 2007). However,
genetic variation associated with baseline TNFSF13B level has
not been reported to predispose patients to CIN. Our pathway-
based analysis identified variant SNP genotypes in the HMMR
gene that were associated with decreased TNFSF13B expression
at baseline and with higher risk of CIN. The potential role of
TNFSF13B is not only activating B-cells but also myeloid cells,
a potential mechanism for how changes in expression of this
gene might predispose patients to treatment related neutropenia.
The mechanism of TNFSF13B expression in association with
neutropenia is unclear and needs to be elucidated.
In addition to the HMMR SNPs, the pathway-based analysis
also identified other SNPs that were significantly associated
with CIN in breast cancer patients. However, those SNPs had
a very low MAF (≤0.051) (Table 2), thus we were unable to
perform functional validation for those SNPs using our 300
LCLs. Those SNPs were included in our pathway-based analysis
because they are located in genes which are involved in the
mTOR, PI3K, P53, and checkpoint pathways (Table 2), pathways
have been found to be aberrant in breast cancer (The Cancer
Genome Atlas Network, 2012). A recent study reported that
common genetic variants for breast cancer risk were negatively
associated with CIN (Dorling et al., 2016). Although that study
used different criteria from ours for selection of SNPs/genes
that correlated with breast cancer risk, they also found that
the P53 signaling pathway was the most enriched pathway
associated with CIN (Dorling et al., 2016). Using a candidate
SNPs/genes approach, SNPs in the TP53 and MDM2 genes, two
most important genes in the P53 signaling pathway, were found
to be associated with CIN in Japanese breast cancer patients
(n = 216) (Okishiro et al., 2012). Of note, the HMMR SNPs
were included in our pathway-based analysis because those SNPs
are located in a gene that is involved in the P53 signaling
pathway (Table 2). It might be interesting to investigate the
relationship between the P53 pathway, TNFSF13B and CIN in
future studies.
Several studies have focused on the SNPs/genes involved in
the cyclophosphamide PK pathway for associations with CIN
in breast cancer patients. These studies reported that SNPs in
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GSTP1 (Yao et al., 2010), ABCC4 (Low et al., 2009) and CYP3A5
(Tang et al., 2013) were associated with CIN in breast cancer
patients. These studies did not include SNPs in CYP2C8 while
our analysis identified a SNP in CYP2C8 that was associated
with CIN (Table 2). Together, those studies indicate that genetic
polymorphisms in the cyclophosphamide PK pathway may be
associated with CIN in breast cancer patients. In addition to
anti-cancer drugs, neutropenia can be also induced by other
drugs such as clozapine, a dibenzodiazepine antipsychotic agent
used for the pharmacotherapy of schizophrenia (Alvir et al.,
1993; Atkin et al., 1996). Pharmacogenomic studies on clozapine-
induced agranulocytosis or neutropenia have often identified
SNPs/genes in the clozapine PK pathway and immune response
genes (Athanasiou et al., 2011; Goldstein et al., 2014; Saito et al.,
2016; Legge et al., 2017; van der Weide et al., 2017), a similar
scenario to pharmacogenomic studies on CIN in breast cancer
patients.
In summary, using a pathway-based approach for analyzing
GWAS data, we identified additional genetic makers for CIN
in breast cancer patients, including SNPs in the HMMR gene.
Further functional genomic studies indicated that HMMR SNP-
dependent sensitivity to chemotherapy is probably dependent on
the expression of TNFSF13B.
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